-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Member Stories: Dr. Ross Soo
Dr. Ross Soo—Singapore In Singapore, a first confirmed case of COVID-19 was reported in late January and, since then, government measures to contain the first wave of infections have resulted to be effective. As part of a whole national plan to control the outbreak, a timely planning of strategies taken by medical oncologists at the National University…
-
Member Stories: Dr. Brendon Stiles
Dr. Brendon Stiles—USA Dr. Stiles is an Associate Professor of Cardiothoracic Surgery at Weill Cornell Medicine (@WeillCornell) and a thoracic surgeon at NewYork-Presbyterian/Weill Cornell Medical Center (@nyphospital). He is vice-chair of the IASLC Communications Committee and extremely active on Twitter (@BrendonStilesMD). New York City has been hit hard by the pandemic. A lot of what…
-
Member Stories: Dr. Anand Sachithanandan
Dr. Anand Sachithanandan—Kuala Lumpur Dr. Anand Sachithanandan is a consultant cardiothoracic surgeon in private practice in greater Kuala Lumpur. He is co-founder and president of Lung Cancer Network Malaysia, an NGO that aims to improve outcomes from lung cancer through awareness, advocacy and education. Offering a comprehensive portrait of the effects of COVID-19 both on…
-
Member Stories: Dr. Narjust Duma
Dr. Narjust Duma—USA Dr. Narjust Duma is a member of the UW Carbone Cancer Center and Assistant Professor of Medicine in the Division of Hematology, Medical Oncology, and Palliative Care. She graduated first in her medical school class at La Universidad Catolica Nordestana in the Dominican Republic. She then completed her internal medicine residency at…
-
Member Stories: Janet Freeman-Daily
Janet Freeman-Daily—USA Janet is a retired aerospace systems engineer, freelance writer, and metastatic lung cancer patient/activist. Diagnosed in 2011, her focus is now on translating the experience and science of lung cancer for others. She serves as a research advocate for two NCCN facilities, the NCI and other government agencies, and as an Editorial Group…
-
IASLC 2020 World Conference on Lung Cancer Postponed
After careful consideration of the current situation, the IASLC Board of Directors and leadership have made the decision to postpone the IASLC 2020 World Conference on Lung Cancer (WCLC 2020), which was scheduled to take place August 9 – 12, 2020, in Singapore. At this time, the World Conference on Lung Cancer has been rescheduled…
-
Déjà Vu, With a Twist: The Vaping Industry’s Approach to Youth-Oriented Advertising Via Social Media
Posted: February 12, 2020 Dr. Lisa Fucito As of early December 2019, the Centers for Disease Control and Prevention (CDC) have received reports from all 50 states, Puerto Rico, the U.S. Virgin Islands, and the District of Columbia comprising 2,291 individuals who were hospitalized for acute lung injury caused by vaping.1 Of these patients, many…
-
Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective
By Lynette M. Sholl, MD, and John W. Longshore, PhD, FACMG Posted: February 12, 2020 Dr. Lynette M. Sholl Dr. John W. Longshore The profound impact of immunotherapy in patients with lung cancer has been described extensively by many experts within the IASLC.1,2 There are, however, broad disparities in outcomes for patients with lung cancer…
-
Increasing the Role of Local Consolidation in Oncogenic-Driven Advanced NSCLC
By Youquan Li, MD, FRCR, and Andrea Bezjak, MDCM, MSc, FRCPC Posted: February 12, 2020 Targeted agents including TKIs of EGFR, ALK, and ROS1 have significantly improved the outcomes of advanced oncogene-driven NSCLC.1,2 Despite initial high response rates, durable and complete responses are rare, and most patients eventually experience treatment failure.3 Residual disease is defined…
-
Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia
Posted: February 12, 2020 Ravi Salgia, MD, PhD, is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences at City of Hope’s Comprehensive Cancer Center. His many decades of research in MET and other oncogenic drivers has helped further lung cancer research and patient care. In the…
View ILCN Archives
Provider Resources
Popular Articles